Manufacturing Lilly and Resilience invest $750M in diabetes and obesity drug device supply BioSpaceThe investment will expand Resilience's U.S.Metabolic & GLP-1Read full story pharminent July 31, 2026 (Last updated: August 3, 2026) BioSpace The investment will expand Resilience’s U.S. Metabolic & GLP-1 Read full story Post navigation Previous: Novo setback casts doubt on a new way to treat heart diseaseNext: Novo Nordisk’s Ziltivekimab Misses Primary Endpoint in Pivotal Cardiovascular Trial Related Stories Manufacturing BMS banks on Texas for $2.3bn multi-modal manufacturing facility pharminent August 11, 2026 Manufacturing AsymBio to secure $184m to support growth in biologics manufacturing pharminent August 5, 2026 Manufacturing GSK Cambridge Move Signals Shift in Drug Scale-Up Strategy pharminent July 29, 2026
